Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
Status:
Completed
Trial end date:
2019-11-20
Target enrollment:
Participant gender:
Summary
The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the
neuroprotectant, Nerinetide (NA-1), in reducing global disability in subjects with major
acute ischemic stroke (AIS) with a small established infarct core and with good collateral
circulation who are selected for endovascular revascularization.